Gilead’s Trodelvy Strategy Helped By Phase II Bladder Cancer Data

 
• By Joseph Haas
  
Antibody-drug conjugate
Gilead continues working toward adding to ADC Trodelvy's label • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D